Need Help?

Whole exome sequencing study of cholesteatoma patients from affected families

This study used whole exome sequencing on 21 patients with cholesteatoma from 10 families in order to identify variants that may attribute to cholesteatoma aetiology. Exomes were enriched for using hybridisation selection and subject to DNA-sequencing. This datasets is formed of two batches as they were sequencing at different times. Batch-1 exomes were selected for using Nimblegen capture (4-plex) and sequenced on Illumina Hiseq 4000 and batch-2 was exome selected using Agilent SureSelect Human All Exon v6 and sequenced on the Illumina NovaSeq 6000. All samples within the same family were processed within the same batch. This dataset is comprised on BAM files mapped using cgpMAP v3.2.0 (bwa-mem) using the GRCh38.

Request Access

This policy provides a summarised version of the data access agreement (DAA) which can be made available to a user upon request.

Below is a summarised version for policies within our data access agreement (DAA), for the release of the data a signed DAA is required. 1. The User Institution is responsible for determining the purposes for which and manner in which it will process the Data after receipt from the Data Producers. 2. The User Institution agrees to only use these Data for the purpose of the Project and only for Research Purposes. 3. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. 4. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 5. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 6. The User Institution warrants that in carrying out its obligations under this agreement it will not breach the Data Protection Legislation or do or omit to do anything that might cause the Data Producers to be in breach of the Data Protection Legislation. 7. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. 8. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 9. The User Institution shall indemnify The Data Producers against any costs, claims, expenses (including reasonable legal costs), damages, liabilities, actions and proceedings brought against the Data Producers by any third party (including but not limited to the Data Subjects) arising out of a breach of this agreement by the User Institution. 10. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). 11. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 12. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 14. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements, and to confirm to the Data Producers when the Data has been destroyed. 15. The User Institution will notify University of East Anglia within 30 days of any changes or departures of Authorised Personnel. 16. The User Institution will notify University of East Anglia prior to any significant changes to the protocol for the Project. 17. The User Institution will notify University of East Anglia as soon as it becomes aware of a breach of the terms or conditions of this agreement, and in any case within 24 hours of becoming aware of any potential or actual security breach or loss of the Data. 18. Any notice given to a party under or in connection with this agreement shall be in writing and addressed to:

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00006132228 1648029960795 759.9 MB
EGAF00006132229 1648029840315 286.5 MB
EGAF00006132230 1648030200210 806.3 MB
EGAF00006132231 1648030260160 4.8 GB
EGAF00006132232 1648029840315 165.3 MB
EGAF00006132233 1648029840314 289.9 MB
EGAF00006132234 1648029840314 231.1 MB
EGAF00006132235 1648029960795 2.1 GB
EGAF00006132236 1648030260160 2.2 GB
EGAF00006132237 1648030200210 4.1 GB
EGAF00006132238 1648030560402 3.5 GB
EGAF00006132239 1648030020152 1.8 GB
EGAF00006132240 1648029900330 832.2 MB
EGAF00006132241 1648030080212 2.8 GB
EGAF00006132242 1648030140337 2.4 GB
EGAF00006132243 1648030020152 350.5 MB
EGAF00006132244 1648030380147 3.3 GB
EGAF00006132245 1648030140337 3.4 GB
EGAF00006132246 1648030140337 3.3 GB
EGAF00006132247 1648029960795 1.6 GB
EGAF00006132248 1648029840314 473.9 MB
EGAF00006132249 1648029900330 344.1 MB
EGAF00006132250 1648029780196 174.5 MB
EGAF00006132251 1648029960795 2.4 GB
EGAF00006132252 1648030200210 2.4 GB
EGAF00006132253 1648029840314 322.6 MB
EGAF00006132254 1648030140337 2.2 GB
EGAF00006132255 1648029900330 205.2 MB
EGAF00006132256 1648029960795 1.8 GB
EGAF00006132257 1648030080212 1.7 GB
EGAF00006132258 1648030200210 707.6 MB
EGAF00006132259 1648029960795 272.0 MB
EGAF00006132260 1648030260160 2.0 GB
EGAF00006132261 1648029960795 1.9 GB
EGAF00006132262 1648030080212 600.3 MB
EGAF00006132263 1648030320075 2.5 GB
EGAF00006132264 1648030020152 2.6 GB
EGAF00006132265 1648030200210 2.4 GB
EGAF00006132266 1648030080212 2.7 GB
EGAF00006132267 1648029900330 273.2 MB
EGAF00006132268 1648030020152 690.8 MB
EGAF00006132269 1648029780196 261.4 MB
EGAF00006132270 1648030320075 1.4 GB
EGAF00006132271 1648029900330 923.9 MB
EGAF00006132272 1648029840314 198.2 MB
EGAF00006132273 1648029840314 275.9 MB
46 Files (70.9 GB)